Atara Biotherapeutics Q2 2024 GAAP EPS $(3.10) Misses $(1.56) Estimate, Sales $28.64M Miss $39.99M Estimate
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics (NASDAQ:ATRA) reported Q2 2024 GAAP EPS of $(3.10), missing the $(1.56) estimate by 98.72%. Sales were $28.64M, missing the $39.99M estimate by 28.38%. Despite the miss, sales increased by 2.89K% from the same period last year.
August 12, 2024 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics reported a significant miss on both EPS and sales estimates for Q2 2024. The EPS of $(3.10) was far below the $(1.56) estimate, and sales of $28.64M missed the $39.99M estimate. Despite the miss, sales increased significantly year-over-year.
The significant miss on both EPS and sales estimates is likely to negatively impact Atara Biotherapeutics' stock price in the short term. However, the substantial year-over-year sales increase may provide some support.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100